Sex differences in age at onset of symptoms in patients with hypertrophic cardiomyopathy

European Journal of Cardiovascular Prevention & Rehabilitation

Volumn 4, Issue 1, 1997, Pages 33-35

  Dimitrow, Pawel Petkow ^a   Czarnecka, Danuta ^b   Jaszcz, Kalina Kawecka ^b   Dubiel, Jacek S ^a  

^a Department of Cardiology ^*  (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

age at symptom onset; hypertrophic cardiomyopathy; women

Indexed keywords

ENDOTHELIUM DERIVED RELAXING FACTOR; ESTROGEN;

ADOLESCENT; ADULT; ARTICLE; ECHOCARDIOGRAPHY; ESTROGEN BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MENARCHE; ONSET AGE; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SURVIVAL; VASODILATATION;

ADOLESCENT; ADULT; AGE OF ONSET; CARDIOMYOPATHY, HYPERTROPHIC; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEX DISTRIBUTION; SEX FACTORS;

EID: 0030790157     PISSN: 17418267     EISSN: 17418275     Source Type: Journal    
DOI: 10.1177/174182679700400106     Document Type: Article

References (23)

1. Frank S, Braunwald E: Idiopathic hypertrophic subaortic stenosis: Clinical analysis of 126 patients with emphasis on the natural history Circulation 1968, 37: 759–788.
2. Whiting RB, Powell JW, Dinsmore RE, Sanders C: Idiopathic hypertrophic subaortic stenosis in the elderly N Engl J Med 1971, 285: 196–200.
3. Krasnow N, Stein RA: Hypertrophic cardiomyopathy in the aged Am Heart J 1978, 96: 326–336.
4. Pelliccia F, Cianfrocca C, De Castro S, Critelli G: Is there a gender gap in clinical presentation and outcome of hypertrophic cardiomyopathy? [abstract] J Am Coll Cardiol 1995, 25 (suppl):107A.
5. Chikamori T, Doi Y, Yonezawa Y, Dickie S, Ozawa T, McKenna WJ: Comparison of clinical features of patients 60 years of age to those 40 years of age with hypertrophic cardiomyopathy Am J Cardiol 1990, 66: 875–877.
6. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE: Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology, and therapy N Engl J Med 1987, 316: 780–789, 844–852.
7. Fay WP, Taliercio C, Illstrup DM, Tajik JA, Gersh BJ: Natural history of hypertrophic cardiomyopathy in the elderly J Am Coll Cardiol 1990, 16: 821–826.
8. Lewis JF, Maron BJ: Elderly patients with hypertrophic cardiomyopathy: A subset with distinctive left ventricular morphology and progressive clinical course late in life J Am Coll Cardiol 1989, 13: 36–45.
9. Topol EJ, Traill TA, Fortuin NJ: Hypertensive hypertrophic cardiomyopathy of the elderly N Engl J Med 1985, 312: 277–283.
10. Motamed HE, Roberts WC: Frequency and significance of mitral anular calcium in hypertrophic cardiomyopathy: Analysis of 200 necropsy patients Am J Cardiol 1987, 60: 877–884.
11. Stice SL, Ford SP, Rosazza JP, Van Orden DE: Role of 4-hydroxylated estradiol in reducing calcium uptake of uterine arterial smooth muscle cells through potential-sensitive channels Biol Reprod 1987, 36: 361–368.
12. Jiang C, Poole-Wilson PA, Sarrel PM, Mockizuki S, Collins P, MacLeod KT: Effect of 17-beta-oestradiol on contraction, calcium current and intracellular free calcium in guinea-pig isolated cardiac myocytes Br J Pharmacol 1992, 106: 739–745.
13. Gilligan DM, Quyyumi AA, Cannon RO: Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women Circulation 1994, 89: 2545–2551.
14. Reis SE, Gloth ST, Blumenthal RS, Resar Jr., Zacur HA, Gerstenblith G etal: Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women Circulation 1994, 89: 52–60.
15. Morgan JP, Morgan KG: Calcium and cardiovascular function: Intracellular calcium levels during contraction and relaxation of mammilan and vascular smooth muscle as detected by aequorin Am J Med 1984, 77 (suppl 5A):33–46.
16. Rosing DR, Idanpaan-Heikkila U, Maron BJ, Bonow RO, Epstein SE: Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy Am J Cardiol 1985, 55: 185B–195B.
17. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV: Verapamil-induced improvement in the left ventricular diastolic and increased exercise tolerance in patients with hypertrophic cardiomyopathy: Short and long term effects Circulation 1985, 72: 853–864.
18. Rosing DR, Kent KM, Maron BJ, Epstein SE: Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy, II: Effects on exercise capacity and symptomatic status Circulation 1979, 60: 1208–1213.
19. Maron BJ, Wolfson JK, Epstein SE: Intramural (‘small vessel’) coronary disease in hypertrophic cardiomyopathy J Am Coll Cardiol 1986, 8: 545–557.
20. Cannon RO, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM etal: Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilatory reserve and elevated left ventricular filling pressure Circulation 1985, 71: 234–243.
21. Kodama K, Kazatani Y, Igase M, Matsuzaki K, Murakami E, Kukubu T: Relation of chest pain and coronary vasospasm in patients with hypertrophic cardiomyopathy [abstract] Circulation 1993, 88 (suppl):I553.
22. Koga Y, Itaya K, Toshima H: Prognosis in hypertrophic cardiomyopathy Am Heart J 1984, 108: 351–356.
23. Geisterfer-Lowrance AT, Christe M, Conner DA, Ingwall JS, Schoen FJ, Seidman CE etal: A mouse model of familial hypertrophic cardiomyopathy Science 1996, 272: 731–734.